title: Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure.
abstract: Congestive heart failure (CHF) is a serious disease with a poor prognosis. Diabetes is an independent risk factor for CHF, probably in part due to disturbances in myocardial metabolism. Glucagon-like peptide-1 (GLP-1) causes glucose-dependent secretion of insulin, improving glycaemic control. In turn, this may improve myocardial metabolism and myocardial function. The aim of the present study was to assess the feasibility and safety of three days' infusion of recombinant GLP-1 in an open observational study in six patients with type 2 diabetes and CHF. The study included assessment of myocardial function. There were no major complications of the infusion, and all patients completed the study protocol. Some improvement was observed in glycaemic state, and there was an insignificant trend towards improved myocardial function. It is concluded that GLP-1 deserves further evaluation in such patients.
authors.affiliation: Department of Cardiology, Karolinska Hospital, Stockholm, Sweden. inga.thrainsdottir@ks.se
authors.forename: Inga
authors.initials: I
authors.lastname: Thrainsdottir
authors.forename: Klas
authors.initials: K
authors.lastname: Malmberg
authors.forename: Arne
authors.initials: A
authors.lastname: Olsson
authors.forename: Mark
authors.initials: M
authors.lastname: Gutniak
authors.forename: Lars
authors.initials: L
authors.lastname: Rydén
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D015150:Echocardiography, Doppler; D005080:Exercise Test; D005934:Glucagon / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007263:Infusions, Parenteral; D007279:Injections, Subcutaneous; D007328:Insulin / Q000097:blood; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D011994:Recombinant Proteins; D052216:Glucagon-Like Peptide 1; D005934:Glucagon